- Home
- ACIU vs EVTL Comparison
ACIU vs EVTL Comparison
Compare ACIU & EVTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- EVTL
- Stock Information
- Founded
- ACIU 2003
- EVTL 2016
- Country
- ACIU Switzerland
- EVTL United Kingdom
- Employees
- ACIU N/A
- EVTL N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- EVTL Aerospace
- Sector
- ACIU Health Care
- EVTL Industrials
- Exchange
- ACIU Nasdaq
- EVTL Nasdaq
- Market Cap
- ACIU 247.4M
- EVTL N/A
- IPO Year
- ACIU 2016
- EVTL N/A
- Fundamental
- Price
- ACIU $1.48
- EVTL $3.45
- Analyst Decision
- ACIU Strong Buy
- EVTL Buy
- Analyst Count
- ACIU 2
- EVTL 6
- Target Price
- ACIU $12.00
- EVTL $11.10
- AVG Volume (30 Days)
- ACIU 192.5K
- EVTL 194.6K
- Earning Date
- ACIU 05-12-2025
- EVTL 03-11-2025
- Dividend Yield
- ACIU N/A
- EVTL N/A
- EPS Growth
- ACIU N/A
- EVTL N/A
- EPS
- ACIU N/A
- EVTL N/A
- Revenue
- ACIU $30,136,397.00
- EVTL N/A
- Revenue This Year
- ACIU N/A
- EVTL N/A
- Revenue Next Year
- ACIU $676.94
- EVTL N/A
- P/E Ratio
- ACIU N/A
- EVTL N/A
- Revenue Growth
- ACIU 84.51
- EVTL N/A
- 52 Week Low
- ACIU $1.43
- EVTL $2.76
- 52 Week High
- ACIU $4.98
- EVTL $15.99
- Technical
- Relative Strength Index (RSI)
- ACIU 24.24
- EVTL 45.20
- Support Level
- ACIU $1.48
- EVTL $3.33
- Resistance Level
- ACIU $1.62
- EVTL $3.60
- Average True Range (ATR)
- ACIU 0.12
- EVTL 0.28
- MACD
- ACIU -0.00
- EVTL 0.08
- Stochastic Oscillator
- ACIU 9.43
- EVTL 81.75
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.